SARS-CoV-2 Seroconversion in Response to Infection and Vaccination: a Time Series Local Study in Brazil

Huergo, Luciano F.; Paula, Nigella M; Gonçalves, Ana C A; Kluge, Carlos H.S; Marins, Paulo H; Camargo, Haxley S. C.; Santana, Thamyres P; Farias, Lucas R; Aldrighi, Juliane Días; Lima, Enio S; Jacotenski, Guiomar T; Vargas, Leticia R; Costa, Gisele; Weissheimer, Karin V.; Nazário, Maria G; Teixeira, Kádima Nayara; Conzentino, Marcelo dos Santos

doi:10.1128/spectrum.01026-22

Cited by 12 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data indicate that more than a quarter of the non-vaccinated cohort had experienced SARS-CoV-2 infection by March 2022. It is worth mentioning that the real number of cases should be higher as IgG anti-N sero-revertes had been detected in this cohort during our previous study (Huergo et al . 2022).…”

Section: Resultsmentioning

confidence: 74%

“…We showed in our previous study that Spike seroconversion in 2021 followed the trend of the population fraction that had taken the second dose (Huergo et al . 2022).…”

Section: Resultsmentioning

confidence: 89%

“…These numbers can be determined based on the fraction of those individuals with a positive IgG test for the N antigen after excluding individuals vaccinated with CoronaVac, the only vaccine applied in Brazil that can elicit anti-N antibodies. In our previous study, serological analysis indicated that 16.7% (12.6 – 20.7, 95% CI) of the population had experienced COVID-19 by the end of 2021 (Huergo et al . 2022).…”

Section: Resultsmentioning

confidence: 93%

“…There are a few studies reporting that the COVID-19 vaccines in use in Brazil can elicit IgG reactive to the Spike antigen (Bochnia-Bueno et al 2021;Medeiros-Ribeiro et al 2021;Grenfell et al 2022;Huergo et al 2022). However, these studies were not designed to compare IgG levels obtained using different vaccines, they were limited to a small cohort and/or a specific group (i.e, heath care professionals) and/or did not provide information regarding the duration of the IgG response, the effectiveness of multiple vaccine doses/boosters nor to the effects of natural infections.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Populational analysis of the immunoglobulin G response to different COVID-19 vaccines in Brazil

Paula

Conzentino

Gonçalves

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Vaccination is a strategy that confers protection against symptomatic infections and/or development of severe COVID-19. In Brazil, COVID-19 vaccination began in January 2021 and has been performed using vaccines from different manufactures including CoronaVac (Sinovac), ChAdOx1 (Oxford/AstraZeneca) and BNT162b2 (Pfizer/BioNTech). One of the main protective mechanisms triggered by vaccination involves the production of IgG antibodies reactive to the Spike antigen of SARS-CoV-2, the levels of which correlates with vaccine efficacy. Although phase III clinical studies confirmed the efficacy of the vaccines used in Brazil, there are just few studies comparing vaccine immunogenicity in a real-world scenario. This study aimed to depict the IgG response to natural infections and to vaccination using different types of vaccines at population scale in Matinhos, a city located in south of Brazil. Nucleocapsid seroconversion rates indicated that more than a quarter of the cohort has been subjected to natural infections by SARS-CoV-2 by the first trimester of 2022. Spike seroconversion rates achieved >95% by February 2022 and maintained stable as far as June 2022 confirming the effectiveness of the vaccination program. Immunogenicity concerning IgG reactive to Spike was higher using the BNT162b2 vaccine, followed by ChAdOx1 and CoronaVac. Natural infections boosted IgG levels reactive to Spike in those individuals that completed primary vaccination with ChAdOx1 and CoronaVac but not with BNT162b2. The levels of IgG reactive to Spike increased with the number of vaccine doses administered. The application of BNT162b2 as booster dose resulted in high levels of IgG reactive to Spike which were similar despite the type of the vaccine used during primary vaccination.

show abstract

Section: Resultsmentioning

confidence: 74%

“…We showed in our previous study that Spike seroconversion in 2021 followed the trend of the population fraction that had taken the second dose (Huergo et al . 2022).…”

Section: Resultsmentioning

confidence: 89%

Section: Resultsmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Populational analysis of the immunoglobulin G response to different COVID-19 vaccines in Brazil

Paula

Conzentino

Gonçalves

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nonetheless, during SARS-CoV-2 infection, antibody responses are variable and generate controversy in terms of immunity and persistence [ 9 ]. Secondly, it is crucial to determine the timing for antibody maintenance after vaccination or even a natural infection [ 10 , 11 ]. This fact acquired a special relevance given that SARS-CoV-2 vaccines, which have already entered phase III clinical trials, arose as a critical solution [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

A Highly Sensitive Immunoassay for Determination of Immune Response to SARS-CoV-2 in Capillary Blood Samples

et al. 2022

View full text Add to dashboard Cite

Throughout the pandemic, serological assays have been revealed as crucial for detecting previous exposures to the virus and determining the timing of antibody maintenance after vaccination or natural infection. This study aimed to develop an optimized enzyme-linked immunosorbent assay (ELISA)-based serology, which could be used in case of reagent shortages, such as that occurred in the beginning of this health emergency. As a result, we present a high-sensitive immunoassay for the determination of IgG levels in venous serum samples, using 2 μg/mL antigen (receptor-binding domain of the spike protein S1) for coating the plate and utilizing human samples at a dilution 1:1000. This method showed non-inferiority features versus a commercial kit, is less expensive, and has a higher spectrophotometric range that allows for a better quantification of the antibody titers. The optical density values before and after heating venous serum samples at 56 °C during 30 min was quite similar, showing that heat inactivation can be used to reduce the biohazardous risks while handling samples. Furthermore, we show that finger-stick capillary blood samples can also serve as a suitable source for IgG detection, bypassing the need for serum isolation and being suitable for point-of-care application (Pearson’s coefficient correlation with capillary serum was 0.95, being statistically significant).

show abstract

Ultrafast and high-throughput immunoassay assay to detect anti-SARS-CoV-2 IgG antibodies in dogs and cats

Gonçalves,

Conzentino,

de Souza Barbosa

et al. 2024

Braz J Microbiol

View full text Add to dashboard Cite

SARS-CoV-2 Seroconversion in Response to Infection and Vaccination: a Time Series Local Study in Brazil

Cited by 12 publications

References 14 publications

Populational analysis of the immunoglobulin G response to different COVID-19 vaccines in Brazil

Populational analysis of the immunoglobulin G response to different COVID-19 vaccines in Brazil

A Highly Sensitive Immunoassay for Determination of Immune Response to SARS-CoV-2 in Capillary Blood Samples

Ultrafast and high-throughput immunoassay assay to detect anti-SARS-CoV-2 IgG antibodies in dogs and cats

Contact Info

Product

Resources

About